MediWound (NASDAQ:MDWD) Announces Earnings Results

MediWound (NASDAQ:MDWD) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57, Zacks reports. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.

MediWound Price Performance

MediWound stock opened at $17.71 on Thursday. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50. The stock has a market capitalization of $196.40 million, a PE ratio of -6.67 and a beta of 0.22. The firm has a 50 day simple moving average of $18.08 and a 200-day simple moving average of $18.85.

Hedge Funds Weigh In On MediWound

A number of hedge funds have recently modified their holdings of the stock. Rhumbline Advisers increased its holdings in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares during the last quarter. Finally, Sargent Investment Group LLC lifted its position in shares of MediWound by 11.1% in the third quarter. Sargent Investment Group LLC now owns 59,926 shares of the biopharmaceutical company’s stock worth $1,080,000 after buying an additional 6,000 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on MDWD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. Zacks Research raised MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, MediWound has a consensus rating of “Moderate Buy” and a consensus target price of $32.25.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.